Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer (scientific article published on 26 January 2011)

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

Q37087122

Beyond chemotherapy: targeted therapies in ovarian cancer

Q37399899

Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy

Q40040127

Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer

Q40048139

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Q40177512

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma

Q40183375

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis

Q40187965

A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1.

Q40331048

Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth

Q40618406

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

Q42463490

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

Q44695868

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Q51761211

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

Q80287572

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

Q80843829

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

ovarian cancer

Q172341

P304

page(s)

8-12

P577

publication date

2011-01-26

P1433

published in

Gynecologic Oncology

Q5625182

P1476

title

Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer

P478

volume

121

Reverse relations

cites work (P2860)

Q37225342	AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines
Q35058443	EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma
Q38717560	Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.
Q37190310	Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
Q64240609	Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma
Q35087191	Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion
Q37616060	Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.
Q34294000	Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study
Q49515435	Meta-analysis of the prognostic value of p-4EBP1 in human malignancies
Q33890763	Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer
Q36962391	MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1
Q34586019	Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma
Q98612773	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
Q35837949	Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways
Q37420213	Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis
Q33698105	Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
Q92565739	Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
Q64269604	The Prognostic Role of Ribosomal Protein S6 Kinase 1 Pathway in Patients With Solid Tumors: A Meta-Analysis
Q36242802	The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Q55225058	The effect of the type of dietary protein on the development of ovarian cancer.
Q24627306	The mTOR signalling pathway in human cancer
Q35005636	The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells
Q36403652	Unfolded protein response to autophagy as a promising druggable target for anticancer therapy
Q37406873	mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix
Q48252712	miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma

P356	DOI	10.1016/J.YGYNO.2010.12.364
P698	PubMed publication ID	21276607